This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Creative BioMart
product type :
antibody
product name :
Anti-PLAU monoclonal antibody, clone 4B219 [FITC]
catalog :
DCABH-5345
quantity :
100 μg
clonality :
monoclonal
host :
mouse
conjugate :
FITC
clone name :
4B219
reactivity :
human
application :
western blot, ELISA
product information
Cat :
DCABH-5345
Product Name :
Anti-PLAU monoclonal antibody, clone 4B219 [FITC]
Brand :
Creative Diagnostics
Abbr :
Anti-PLAU MAb, FITC-Conjugated
Host animal :
Mouse
Clone :
4B219
Official Symbol :
PLAU
Clonality :
Monoclonal
Application :
WB, ELISA
Target :
PLAU
Species Reactivity :
Human
Conjugate :
FITC
Antibody Type :
Primary Antibodies
Immunogen :
Full length protein corresponding to Human Urokinase. The glycosylated wild-type protein was used as the immunogen.
Alternative Names :
PLAU; plasminogen activator, urokinase; urokinase-type plasminogen activator; UPA; URK; U-plasminogen activator; plasminogen activator, urinary; ATF; QPD; u-PA; BDPLT5;
UniProt ID :
P00749
Antibody Isotype :
IgG
Size :
100 μg
Storage :
Store at +4°C.
company information

Creative BioMart
Creative BioMart provides quality recombinant proteins, diagnostic antibodies and antigens, diagnostic enzymes and pharmaceutical enzymes to the research community of biology, clinical research, molecular diagnostics and biopharmaceutical drug development.
We are offering more than 3,000 recombinant proteins, peptides and antibodies. All the products are rigorously tested to meet the most demanding research needs. At the same time, lowest prices in the industry are always guaranteed.
Also, in order to leverage our core competencies and resources, Creative BioMart has formed a large number of corporate partnerships and academic collaborations for product development and distribution. We welcome potential partners and distributors to explore business relationships with Creative BioMart.
questions and comments